Sanofi to buy immunology biotech Blueprint for US$9.1 billion
Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare immunological ...
Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare immunological ...
France’s Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its position in ...
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as ...
China is seeking to strengthen economic ties with individual members of the European UnionSanofi plans to invest around US$1.05 billion ...
Modulus can also be reconfigured within a few days to transform between technological platforms, a process which traditionally takes months ...
Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling ...
Doliprane is France’s best-selling drug and news that it could be partially sold to a foreign investor has prompted political ...
BANKS and other lenders are lining up more than 10 billion euros (S$14.3 billion) of debt to back a buyout ...
Sanofi and Novavax signed a licensing agreement that includes commercialising a combined Covid-19 and flu shot. Novavax will receive US$500 million ...
The NY Journals pride themselves on assembling a proficient and dedicated team comprising seasoned journalists and editors. This collective commitment drives us to provide our esteemed readership with nothing short of the most comprehensive, accurate, and captivating news coverage available.
Transcending the bounds of New York City to encompass a broader scope, we ensure that our audience remains well-informed and engaged with the latest developments, both locally and beyond.
© 2025 The New York Journals. All Rights Reserved.